- Sponsor: National Institutes of Health (NIH)
- Internal Deadline: September 8, 2020
- Sponsor LOI Deadline: November 7, 2020
- Sponsor Deadline: December 7, 2020
- Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-035.html
The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV.
Please read the full program announcement before preparing your internal application.
- Application budgets are limited to $3.5 million direct costs per year and should reflect the actual needs of the proposed project.
- The total project period must be 5 years.
- Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
- Only one application per institution is allowed to be submitted to either this FOA or the companion FOA for the Martin Delaney Collaboratories for Pediatric HIV Cure Research (RFA-AI-20-036). An institution may not submit one application to this FOA and one application to the Pediatric MDC FOA. However, a given institution may receive funds through subawards from more than one application.
- Detailed review criteria can be found here.
An Institution may submit one proposal to this FOA or the companion FOA for the Martin Delaney Collaboratories for Pediatric HIV Cure Research (RFA-AI-20-036). An institution may not submit one application to this FOA and one application to the Pediatric MDC FOA. However, a given institution may receive funds through subawards from more than one application.
If you are interested in submitting for this program, you must first submit an internal application to email@example.com according to the required instructions below.
Internal Applications must include the following:
- A cover page listing
- The name of this funding opportunity and title of your proposal
- Your name, UGA position, home department, email, and UGA contact information
- Collaborator names, positions, and institutions (if any)
- Indicate whether or not you have submitted to this program in the past. If so, please provide a copy of the review at the end of the internal application.
- A (maximum two-page) proposal summary that addresses the program’s specific selection criteria.
- One paragraph describing why this proposal should be UGA’s submission (i.e., why it will be the most competitive for this program)
- Curriculum vitae
Limited Submission announcements often generate multiple competing proposals. UGA reviewers judge proposals as they would in any peer review process, so PIs are urged to put their best foot forward. Along with typical criteria, reviewers will evaluate internal proposals based on their fit with the sponsor’s articulated goals and criteria.
Internal Submission Instructions
The above internal application materials should be submitted via email as a single .PDF file to firstname.lastname@example.org by the internal deadline listed above.
Please submit questions regarding the internal competition to email@example.com.
For questions directly related to this program, please contact the following program officers:
National Heart, Lung, and Blood Institute
Karl Salzwedel, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Peter J. Perrin, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Vasundhara Varthakavi, D.V.M., Ph.D.
National Institute on Drug Abuse (NIDA)
Jeymohan Joseph, Ph.D.
National Institute of Mental Health (NIMH)
May Wong, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
View our calendar for all Current and Closed Limited Submissions.
Subscribe to our listerv to receive weekly internal competition announcements.
What is a Limited Submission?